Vulvar squamous cell hyperplasia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 05 Jun 2026 10:52:41 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Vulvar squamous cell hyperplasia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Pembrolizumab for Patients with Vulvar Squamous Cell Carcinoma https://clinicaltrials.eu/trial/study-of-pembrolizumab-for-patients-with-vulvar-squamous-cell-carcinoma/ Wed, 29 Apr 2026 14:59:42 +0000 https://clinicaltrials.eu/trial/study-of-pembrolizumab-for-patients-with-vulvar-squamous-cell-carcinoma/ This clinical trial is focused on studying vulvar squamous cell carcinoma, a type of cancer that affects the vulva. The treatment being tested is called pembrolizumab, which is also known by its brand name, KEYTRUDA. Pembrolizumab is a medication that is given through an intravenous infusion, meaning it is delivered directly into the bloodstream through a vein. The purpose of the study is to explore how effective pembrolizumab is when used before surgery to reduce the size of the tumor.

Participants in the study will receive pembrolizumab and will be monitored to see how the tumor responds to the treatment. The study will also look at how the body’s immune cells, specifically a type of cell called effector T cells, react to the treatment. These cells are part of the immune system and help fight cancer. The study will last for several weeks, with the first assessment of the tumor size taking place approximately six weeks after the first dose of pembrolizumab.

The trial aims to gather information on the safety and effectiveness of pembrolizumab in treating vulvar squamous cell carcinoma. Researchers will also observe any changes in the tumor and the behavior of immune cells during the treatment. This study is an important step in understanding how pembrolizumab can be used to help patients with this type of cancer.

]]>